TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells $380,480.00 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 4,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total value of $380,480.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at approximately $7,047,155.44. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

TransMedics Group Price Performance

NASDAQ:TMDX traded down $0.62 during trading hours on Thursday, hitting $87.24. 692,313 shares of the stock were exchanged, compared to its average volume of 688,977. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $99.63. The firm’s fifty day moving average price is $83.01 and its 200 day moving average price is $72.88. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The company had revenue of $81.20 million during the quarter, compared to analyst estimates of $68.49 million. During the same period in the previous year, the business earned ($0.21) EPS. TransMedics Group’s quarterly revenue was up 158.6% on a year-over-year basis. On average, equities analysts expect that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on TMDX. Oppenheimer upped their price target on TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. JPMorgan Chase & Co. upped their price target on TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. Morgan Stanley upped their price target on TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. Finally, Piper Sandler assumed coverage on TransMedics Group in a report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price target for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $102.00.

Institutional Investors Weigh In On TransMedics Group

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of TransMedics Group by 1.7% in the third quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock valued at $99,341,000 after purchasing an additional 29,798 shares in the last quarter. Moody Aldrich Partners LLC grew its position in shares of TransMedics Group by 110.3% in the fourth quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock valued at $3,655,000 after purchasing an additional 24,290 shares in the last quarter. American Century Companies Inc. grew its position in shares of TransMedics Group by 271.2% in the third quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock valued at $26,661,000 after purchasing an additional 355,755 shares in the last quarter. Eagle Health Investments LP grew its position in shares of TransMedics Group by 78.5% in the third quarter. Eagle Health Investments LP now owns 414,205 shares of the company’s stock valued at $22,678,000 after purchasing an additional 182,173 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its position in shares of TransMedics Group by 31.2% in the third quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock valued at $4,624,000 after purchasing an additional 20,081 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.